Nafamostat mesilate is an effective agent for an anti-hypercoagulable state after administration of andexanet alfa to safely initiate CPB due to its anticoagulant effect regardless of antithrombin III and a short life of 8 min. This evidence concerns the gene SERPINC1 and thrombophilia.